» Articles » PMID: 30941804

Characteristics and Outcomes of Young Adults with Philadelphia-negative Myeloproliferative Neoplasms

Overview
Journal Eur J Haematol
Specialty Hematology
Date 2019 Apr 4
PMID 30941804
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Approximately 10% of Philadelphia (Ph)-negative myeloproliferative neoplasms (NPM) are diagnosed at young adulthood. We aim to define the features of this group.

Methods: A multicenter retrospective study, including patients 18-45 years of age, diagnosed with Ph-negative MPN between 1985 and 2017.

Results: One hundred nine patients were included, 37 with polycythemia vera (34%), 54 with essential thrombocytosis (50%), 15 with primary myelofibrosis (PMF) (14%), and 3 with MPN unclassifiable (3%). Median age was 33 years and 62 (57%) were females. During a median follow-up of 8 years, 39 patients (37%) had at least one thrombotic event. 30/39 of events were venous (77%), 23/30 of which were splanchnic (77%). In 14/39 (36%), thrombosis preceded MPN diagnosis. In a multivariable analysis, only splenomegaly predicted for thrombosis (HR 5.6, CI: 1.4-22). The 10-year risk for secondary myelofibrosis was similar for ET and PV (0.13 vs 0.19, P = 0.51). The 10-year risk for leukemic transformation or mortality was significantly higher for PMF (0.3, P = 0.04).

Conclusions: The risks of mortality and of progression to MF/leukemia in young adults are similar to older population. Thrombotic events are frequently a presenting sign with a high incidence of venous, in particular splanchnic, events.

Citing Articles

Impact of treatment for adolescent and young adults with essential thrombocythemia and polycythemia vera.

Beauverd Y, Ianotto J, Thaw K, Sobas M, Sadjadian P, Curto-Garcia N Leukemia. 2025; .

PMID: 40074852 DOI: 10.1038/s41375-025-02545-2.


Clinical characteristics in adolescents and young adults with polycythemia vera and essential thrombocythemia in Japan.

Sugimoto Y, Nagaharu K, Ohya E, Ohishi K, Tawara I, Ito T Int J Hematol. 2024; 120(6):684-693.

PMID: 39467899 DOI: 10.1007/s12185-024-03862-5.


Myeloproliferative neoplasms: young patients, current data and future considerations.

Sobas M, Ianotto J, Kiladjian J, Harrison C Ann Hematol. 2024; 103(9):3287-3291.

PMID: 39110200 DOI: 10.1007/s00277-024-05920-8.


Myeloproliferative neoplasms in the adolescent and young adult population: A comprehensive review of the literature.

Goulart H, Masarova L, Mesa R, Harrison C, Kiladjian J, Pemmaraju N Br J Haematol. 2024; 205(1):48-60.

PMID: 38853641 PMC: 11245372. DOI: 10.1111/bjh.19557.


Clinical Features and Long-Term Outcomes of a Pan-Canadian Cohort of Adolescents and Young Adults with Myeloproliferative Neoplasms: A Canadian MPN Group Study.

England J, Szuber N, Sirhan S, Dunne T, Cerquozzi S, Hill M Leukemia. 2024; 38(3):570-578.

PMID: 38321107 DOI: 10.1038/s41375-024-02155-4.